Merck & Co., Inc. (MRK) Starts Phase 3 Trial of OHTUVAYRE for COPD Exacerbations
阅读少于1分钟
Merck began enrolling patients in ENHANCE-3, a Phase 3 trial evaluating OHTUVAYRE plus standard of care to prevent COPD exacerbations. The study plans to enroll approximately 2,136 patients in 28 countries; no prior-period comparison was provided.
Material Details
| # | Detail | AI Analyst View |
|---|---|---|
| 1 | Phase 3 trial plans ~2,136 patients in 28 countries | A large global study advances OHTUVAYRE into a new COPD-prevention use, but results and commercial impact remain uncertain. |
| 2 | Enrollment has begun; first patients enrolling in U.S. | Trial execution is underway, but no efficacy or safety results were disclosed. |
| 3 | Primary endpoint: annualized moderate/severe exacerbations | The endpoint will test whether the drug reduces exacerbations beyond standard care. |
| 4 | OHTUVAYRE FDA-approved for COPD maintenance in June 2024 | The trial builds on an existing approved product; the release provides no sales or revenue impact. |
Context by AI Analyst
This is an early-stage expansion of OHTUVAYRE's development, following its 2024 FDA approval for COPD maintenance treatment. The next catalyst is ENHANCE-3's results on exacerbation rates and secondary endpoints, which Merck says it will share with regulatory authorities globally.
Based on the original press release from Merck & Co., Inc. distributed by BusinessWire.
This is an AI-generated summary and may contain inaccuracies. Summary is based on content distributed by BusinessWire. Please verify any important information with the original source. This information is not a recommendation for what you should do personally and does not constitute investment advice.
© 2026 Business Wire, Inc., All rights reserved.